Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Humira Filed for nr-axSpA in Japan Based on Public Knowledge: AbbVie
September 2, 2024
- UCB’s Anti-Epileptic Drug Briviact Now Available in Japan
September 2, 2024
- Majority of PNH Patients Expected to Switch to Novartis’ Fabhalta: Expert
August 30, 2024
- AstraZeneca Japan Launches Research on Lung Cancer Survival Rate Using National Registry
August 30, 2024
- JCR’s JR-441 Primed for Japan Clinical Trial in MPS IIIA
August 30, 2024
- Personal Info of Over 700,000 People Potentially Leaked: Sanofi Japan
August 29, 2024
- Sawai Nabs Distribution Rights to CureApp’s Alcoholism Therapy App
August 29, 2024
- Chugai to Divest Oxarol Injection to LTL in Japan
August 29, 2024
- Padcev-Keytruda Approved in Europe for 1st Line Bladder Cancer
August 29, 2024
- Takeda Rolls Out CMV Drug Livtencity in Japan
August 29, 2024
- Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
August 28, 2024
- Sanofi Curbs Supply of Ultra-Fast Acting Insulin Biosimilars in Japan
August 28, 2024
- PNH Drug PiaSky Approved in Europe: Roche/Chugai
August 28, 2024
- Astellas’ Hot Flash Drug Now in Global PIII for Women with Breast Cancer
August 28, 2024
- Guardant Liquid Biopsy Test Approved as CDx for Amivantamab Combo Therapy
August 28, 2024
- A Time for Patience - 4: Toho University Joins Ionis’ Global Trial for FUS-ALS
August 27, 2024
- Mitsubishi Walks Away from Collategene Deal with AnGes
August 26, 2024
- GSK Introduces Asthma Drug Relvar for Children in Japan
August 26, 2024
- A Time for Patience - 3: As iPSC-Based Drug Discovery Advances, Will 2 Existing Meds Be Repurposed for ALS?
August 26, 2024
- UK OKs Eisai’s Alzheimer’s Drug, but Health Coverage Nixed
August 26, 2024
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…